Mahana is a US-based company developing digital chronic condition management programs that are designed to empower patients with chronic conditions to live fuller lives. Mahana’s self-guided, digital chronic condition management programs employ a proprietary cognitive behavioral therapy (CBT) platform that complements consumer health and pharmacological treatments to address high unmet needs associated with digestive, hearing, dermatology, and women’s health chronic conditions. When used with standard of care treatments, these programs can dramatically improve outcomes, patient treatment satisfaction, quality of care and overall patient quality of life while reducing associated provider workload burden.

Mahana announced the acquisition of Berlin-based Cara Care (previous portfolio company of Asabys) in March 2024. The combination created a global company offering the most comprehensive digestive health portfolio currently addressing Irritable Bowel Syndrome (IBS), Irritable Bowel Disorder (IBD), Celiac Disease and Heartburn, with an exciting pipeline focused on Tinnitus, Pruritus, and Vulvodynia. The combined entity is poised to expand its commercialization efforts beyond Germany to France and the United Kingdom as reimbursement of digital programs continues to improve across Europe.